Serlopitant

Serlopitant
Clinical data
Routes of; administration	By mouth
ATC code	None;
Identifiers
	IUPAC name 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one;
CAS Number	860642-69-9;
PubChem CID	23653789;
ChemSpider	24686685;
UNII	277V92K32B;
KEGG	D09378;
ChEMBL	ChEMBL447955;
CompTox Dashboard (EPA)	DTXSID701006599 ;
Chemical and physical data
Formula	C29H28F7NO2
Molar mass	555.527 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5;
	InChI InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1; Key:FLNYCRJBCNNHRH-OIYLJQICSA-N;

Serlopitant (INN,^[1] codenamed VPD-737) is a drug which acts as an NK₁ receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development.^[2]^[3]

References

^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 62" (PDF). World Health Organization. 2009. pp. 261–2. Retrieved 17 November 2016.
^ Frenkl, TL; Zhu, H; Reiss, T; Seltzer, O; Rosenberg, E; Green, S (August 2010). "A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder". The Journal of Urology. 184 (2): 616–22. doi:10.1016/j.juro.2010.03.147. PMID 20639026.
^ Payton, S (August 2010). "Urinary Incontinence: Neurokinin Receptor Antagonist Inferior to Tolterodine for OAB". Nature Reviews Urology. 7 (8): 418. doi:10.1038/nrurol.2010.105. PMID 20726068.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.